C

Cencora

Distributes medicines and supports patient care

Product Owner 2

Full-TimeUpdated on 10/24/2026
No salary listed
Junior
Bachelor's, Certification
Remote in Poland+1 moreMore locations: Lublin, Poland
Remote
ProductProduct Management

About the job

Requirements
  • A bachelor's degree in a related field or equivalent demonstrable experience as a Product Owner or Product Manager is required.
  • At least one year of experience as a Business Analyst, Product Owner, or Product Manager is required.
  • Experience using AI tools and generative AI is required.
  • English fluency is required.
  • Experience performing requirements analysis and writing specification documents to deliver customer outcomes is required.
  • Experience delivering products using agile development methodologies and working directly with developers or technical teams is required.
  • Experience interpreting data and translating it into stories to drive product strategy is required.
  • A deep understanding of product-specific market personas and their challenges is required.
  • Experience defining user journeys and stories and setting quality story standards is required.
  • Requirements analysis, ideally including SaaS and managed service products, is required.
  • Agile Scrum knowledge is required.
  • Experience using Jira is required.
  • Ability to write behavior-driven development specifications and understand Cucumber/Gherkin is required.
  • Ability to derive and document non-functional requirements is required.
  • Backlog management and refinement skills are required.
  • Understanding of software development lifecycle processes is required.
  • Understanding of user experience and product design is required.
  • A bachelor's degree in business administration, marketing, economics, engineering, information systems, or a related field, or equivalent experience, is required.
  • Less than two years of experience in product management, product operations, business analysis, market research, project coordination, or a related field is required.
Responsibilities
  • Lead cross-functional product delivery with development, engineering, and other internal teams to deliver products, features, and releases aligned with product vision, roadmap, business objectives, and market needs.
  • Identify customer problems and bring cross-functional teams together to deliver products that meet customer needs and drive business growth.
  • Collaborate with the Product Manager, UX team, and other stakeholders.
  • Manage scope to timescales and budget.
  • Represent users in digital product decisions.
  • Collect, manage, and prioritize product features and requirements from internal and external stakeholders according to business value.
  • Define user journeys and translate identified needs into clear, prioritized product requirements.
  • Maintain a prioritized backlog of user stories and bugs, balancing business needs with technical debt, security, and other priorities.
  • Facilitate product demonstrations and feedback activities to validate delivered functionality and inform future priorities, including organizing ongoing sprint demos to collect stakeholder feedback.
  • Produce testable user stories that meet the definition of ready, deliver value within a single sprint, and align with solution objectives.
  • Ensure non-functional requirements are well documented and testable.
  • Ensure requirements consider system configuration options and define appropriate defaults.
  • Ensure requirements address application security and align with development processes and regulatory and compliance guidelines.
  • Use generative AI to help create user and functional requirements, applying judgment about when to use AI.
  • Take on additional reasonable tasks aligned with the employee's abilities when required.
Desired Qualifications
  • Experience working with pharmaceutical software, electronic trial master files (eTMFs), pharmacovigilance, and/or regulatory affairs tools is preferred but not essential.
  • A certification in product management, agile practices, or business analysis is preferred.

About the company

Cencora buys and distributes medicines for pharmacies, hospitals and physician practices, while helping drug manufacturers bring treatments to patients. Its businesses combine wholesale supply networks with specialty distribution for complex therapies and services that support prescribing and patient access. Customers order medicines through its distribution systems, and its teams manage sourcing, storage and delivery alongside pharmacy operations and manufacturer support. It earns revenue from pharmaceutical sales and fees for logistics and healthcare services. The parent company was formed in 2001 through the merger that created AmerisourceBergen, adopted the Cencora name in 2023, and is headquartered in Conshohocken, Pennsylvania.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

2001

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharmacy contracts deepen customer ties: Cencora negotiates insurer agreements and handles administrative work through its managed-care networks.
  • Eligible US staff gain retirement support: Cencora counts student-loan payments toward its employer match, up to 4% of pay.
  • Drug demand expands sales: Cencora reported 5.1% quarterly revenue growth in August 2026, led by higher US volumes.

What critics are saying

  • Customer dependence concentrates risk: Walgreens and Boots supplied 25% of Cencora's fiscal 2025 revenue, reported in November 2025.
  • Legal liabilities tie up cash: Cencora's November 2025 filing recorded $4.3 billion in opioid settlements, payable over 13 years.
  • Warehouse work is physical: Cencora's day-shift associate listing requires repeated lifting up to 50 pounds and overtime availability.

What makes Cencora unique

  • Independent pharmacies get a shared brand: Cencora's Good Neighbor Pharmacy franchise supports their merchandising and store identity.
  • Specialty shipments use reusable packaging: Cencora's World Courier Cocoon containers combine passive temperature control with live location monitoring.
  • Medicines arrive ready for bedside checks: Cencora's American Health Packaging sells barcoded unit doses that support hospital scanning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Parental Leave
  • Adoption Assistance
  • Infertility Coverage
  • Family Planning Benefits
  • Behavioral Health Solutions
  • Professional Development Budget
  • Training Programs

Company News

Financial News
Oct 21st, 2026
Cencora to buy American Oncology Network in $2.4bn deal

Cencora agrees to buy American Oncology Network for $2.4bn enterprise value, but a stockholder rollover means it may land only 75% of the company.

Yahoo Finance
Oct 16th, 2026
Cencora stock: $332.8B revenue, 14.4% EPS growth and 50.2% ROIC

Cencora, the pharmaceutical distributor formerly known as AmerisourceBergen, has risen 6% to $341.69 per share over the past six months. The S&P 500 gained 9.7% in the same period. The New York Stock Exchange-listed company (NYSE:COR) connects drug manufacturers with healthcare providers and offers logistics, data analytics, and consulting services. It rebranded in 2023. Its revenue reached $332.8 billion over the past 12 months, giving it scale and bargaining power with suppliers. That matters in a low-margin, volume-driven business. Earnings per share grew at a 14.4% compound annual rate over five years, outpacing 10.2% annualised revenue growth. Its five-year average return on invested capital was 50.2%. The shares trade at 17.4 times forward earnings.

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.